Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.

doi:10.21203/rs.3.rs-1452239/v1

PDF

Research Article

Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.

https://doi.org/10.21203/rs.3.rs-1452239/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 11 Apr, 2022

You are reading this latest preprint version

Background

This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment.

Methods

We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05).

Results

Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female (n = 944, 51.6%), < 70years-old (n = 1149, 62.8%), had larynx cancer (n = 789, 43.1%) in T4 (n = 579, 47.7%), N0 (n = 509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles (n = 1072, 58.5%) of < 400mg (n = 996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26–3.75), > 70 years-old patients (OR = 16.02, CI95% = 11.99–21.41), with HHNR (OR = 1.84, 1.41–2.40), treated with > 4 cycles (OR = 1.52, CI95% = 1.16–2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52–5.71) are the greatest risk factors for OM.

Conclusion

Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution.

Mucositis

Cetuximab

Antibodies

Neoplasm

Antineoplastic Agents

The therapeutic protocols usually applied for cancer treatment involve surgical intervention, radiotherapy, and/or chemotherapy, but the advance in the use of neoadjuvant, adjuvant, and palliative chemotherapy has significantly increased life expectancy in the treatment of most solid tumors [1]. The major disadvantage of chemotherapy with cytotoxic agents is that despite destroying cancer cells, most chemotherapeutic agents do not act selectively to identify malignant and normal cells, especially fast-growing ones such as gastrointestinal, capillary, and immune cells [2]. Adjuvant treatment with monoclonal antibodies (immunotherapy) has significantly innovated traditional cancer treatment. These drugs specifically inhibit tumor growth signaling pathways, induce immune responses against tumor cells, and preserve more healthy cells, concerning traditional antineoplastic treatment protocols [3].

Human genome studies have enabled advances in technologies that detect genomic alterations at the transcription and epigenetic levels. Combining these technologies with new drugs under development constitutes the implementation of targeted therapies [4]. Cetuximab is a recent drug used in monotherapy or combination with local radiotherapy. It is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR) [5].

Cetuximab acts by competitively inhibiting the binding of EGFR to its ligand with consequent blockade of phosphorylation of receptor-related enzymes to suppress cell growth, induce cell apoptosis, and reduce the production of cytokines that stimulate degradation of the medium [6]. Cetuximab induces apoptosis of tumor cells and keeps them in the G1 phase when they are relatively sensitive to radiotherapy. It also reduces radiotherapy-resistant S phase cells, thus increasing their sensitivity to radiotherapy treatment [7].

Still, despite its high specificity, cetuximab has been associated with dermatitis, especially oral mucositis [8, 9]. Oral mucositis occurs due to the cytotoxic effect of antineoplastic drugs on the oral mucosa. Its consequence is an erosive inflammation leading to dysphagia, taste alterations, weight loss, and secondary infections [10, 11,]. The incidence of mucositis associated with antineoplastic chemotherapies, and their severity, depends on the antineoplastic agent, doses, and treatment time. Therefore, studies evaluating risk factors for this condition have been widely developed [12, 13].

However, some authors have speculated that oral mucositis related to monoclonal antibodies has distinct mechanisms, apparently linked to hypersensitivity [9, 14] or inflammatory vasculitis [15]. In this context, knowing the risk factors for oral mucositis related to cetuximab may contribute to the understanding of its mechanisms, as well as help to understand risk groups and define prevention/treatment protocols. Thus, this study aims to evaluate risk factors for oral mucositis related to using cetuximab in patients undergoing systemic treatment for solid tumors.

5.1. Study design and scenario

This study is a retrospective, quantitative observational cohort study guided by the STROBE initiative, an international guideline for conducting observational studies [16]. This study was conducted using data on oral cavity adverse effects in patients during chemotherapy to treat solid tumors available in the electronic patient record system of the Haroldo Juaçaba Hospital/Ceará Cancer Institute (HHJ/ICC) from January 1, 2010, to December 31, 2019.

The Ethics Committee of the Haroldo Juaçaba Hospital approved this research as part of a project that includes the analysis of risk factors for adverse effects of cancer treatment in the oral cavity, whose protocol number is 4.062.135. All study phases were carried out under law 466/12 of the research ethics legislation, ensuring the confidentiality of information from the patients' medical records and keeping them until the end of the study.

5.2. Inclusion and exclusion criteria

The inclusion criterion was patients who had performed at least one zoledronic acid infusion in the period from January 1, 201 8to December 31, 2019, at the HHJ/ICC. All drug infusions in chemotherapy services of the Unified Health System or private health insurance plans are recorded in the Tasy system with the pharmaceutical record of the active ingredient of the drug. Thus, we retrieved the services when these patients took their doses, utilizing this system.

The exclusion criteria were patients undergoing treatment for myeloproliferative disorders, occult or metastatic disease with an unknown primary site, and those with medical records lacking clinical information required to assess risk factors. Repeated patients (> 1 evaluation) were also excluded.

5.3. Socio-demographic and clinical data collection

With the number of services provided by the Tasy system's toxicity scale tool, we performed a manual search of each service's records to retrieve the clinical and pathological data of interest. Patients appearing more than once were ordered by their date of care to identify the number of chemotherapy cycles.

During the manual collection of information based on the number of care visits, the patients' medical records were collected, as well as age, sex, weight on the day of care, height, chemotherapy purpose (neoadjuvant, adjuvant, or palliative), clinical stage, chemotherapy protocol, and primary tumor location. Additionally, the tumor-node-metastasis (TNM)-2016 grading system [17] was used to classify the stage of the solid tumors. Information on previous/concomitant head and neck radiotherapy was obtained from head and neck tumors patients. All data were recorded using a Microsoft Excel spreadsheet.

5.4. Adverse effects analysis tool

The toxicity scale tool used was the Common Terminology Criteria for Adverse Events (CTCAE). Formerly called the Common Toxicity Criteria (CTC or NCI [National Cancer Institute]-CTC), this tool contains a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI). It has been widely used in many clinical trials, extending beyond oncology and encoding their observations based on the CTCAE system [18].

The CTCAE system toxicity scale includes the following adverse effects: mucositis, vomiting index, diarrhea, nausea, constipation, anorexia, dysgeusia, alopecia, hand and foot syndrome, fatigue, insomnia, and dysuria. All patients were classified according to toxicity scores suggested by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects. It uses a range of grades from 1 to 5. Still, specific conditions such as dysgeusia are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of moderate pain and ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention) [18].

After each medical consultation performed immediately before chemotherapy, the multi-professional team assigned the following toxicity grades for dysgeusia registered in the toxicity scale tool and exported to a standard Microsoft Excel spreadsheet containing the number and date of attendance and the degree of severity of the adverse effect. Patients with > 1 evaluation were excluded.

5.5. Statistical approach

The data were exported to IBM SPSS Statistics for Windows, Version 20.0, to perform the statistical analyses and obtain 95% confidence intervals.

The prevalence of oral mucositis grades was expressed as an absolute frequency and percentage compared to the risk factors using Fisher's exact or Pearson's chi-square tests. We included p < 0.200 variables in a multinomial logistic regression model (multivariate analysis).

A total of 1831 patients were evaluated in this study. The prevalence of oral mucositis was 41.0%, with 750 patients experiencing this adverse effect after treatment with cetuximab (Fig. 1).

Most of the patients evaluated in female (n = 944, 51.6%), and the mean age was 66.3 ± 8.52 years, ranging from 42 to 81. Patients were categorized based on median age, showing 1149 (62.8%) patients aged up to 70 years and 682 (37.2%) aged over 70 years. Female gender (p < 0.001) and age over 70 years (p < 0.001) showed an increased prevalence of oral mucositis associated with cetuximab use (Table 1).

The most frequently treated cetuximab tumors were laryngeal (n = 789, 43.1%) followed by colorectal (n = 30.3%). Tumors of the mouth, glottis, and larynx had a higher prevalence of oral mucositis associated with cetuximab use (p < 0.001) (Table 1).

Table 1

Influence of gender, age, and tumor location on the prevalence of oral mucositis in patients taking cetuximab.
		Oral Mucositis
	Total	No	Yes	p-Value
Total	1831 (100.0%)	1081 (59.0%)	750 (41.0%)	-
Sex
Female	944 (51.6%)	442 (46.8%)	502 (53.2%)*	< 0.001
Male	887 (48.4%)	639 (72.0%)*	248 (28.0%)
Age
Up to 70 years old	1149 (62.8%)	927 (80.7%)*	222 (19.3%)	< 0.001
> 70 years old	682 (37.2%)	154 (22.6%)	528 (77.4%)*
Site
Mouth	138 (7.5%)	53 (38.4%)	85 (61.6%)*	< 0.001
Nasopharinx	210 (11.5%)	162 (77.1%)*	48 (22.9%)
Glottis	87 (4.8%)	9 (10.3%)	78 (89.7%)*
Larynx	789 (43.1%)	407 (51.6%)	382 (48.4%)
Colon	555 (30.3%)	398 (71.7%)*	157 (28.3%)
Non-melanoma skin	52 (2.8%)	52 (100.0%)*	0 (0.0%)
*p < 0.05, Pearson's chi-square test (n, %)

Regarding staging, T4 stage (n = 579, 47.7%) N0 stage (n = 509,52.6%) were the most prevalent stages, and T1 (p < 0.001) and N0/N2 (p < 0.001) tumors showed a higher prevalence of oral mucositis associated with the use of cetuximab. Tumor resection surgery was described in most cases (n = 1476, 80.6%) and head and neck radiotherapy in 606 (33.1%) patients, the latter being directly associated with oral mucositis (p < 0.001) (Table 2).

Most patients had two cycles of treatment with cetuximab (n = 560, 30.6%) (Fig. 1), but the number of cycles of chemotherapy did not significantly influence the incidence of mucositis. The most frequently used doses of cetuximab were less than 400mg (n = 996, 54.4%), and doses greater than 600mg of cetuximab significantly increased the incidence of oral mucositis (Table 2).

Table 2

Influence of clinical features and therapeutic protocol on the prevalence of oral mucositis in patients taking cetuximab.
		Oral Mucositis
	Total	No	Yes	p-Value
T
1	432 (35.6%)	86 (19.9%)	346 (80.1%)*	< 0.001
2	88 (7.3%)	40 (45.5%)	48 (54.5%)
3	114 (9.4%)	35 (30.7%)	79 (69.3%)
4	579 (47.7%)	463 (80.0%)*	116 (20.0%)
N
0	509 (52.6%)	132 (25.9%)	377 (74.1%)*	< 0.001
1	409 (42.3%)	285 (69.7%)*	124 (30.3%)
2	50 (5.2%)	12 (24.0%)	38 (76.0%)*
Primary tumor surgery
No	355 (19.4%)	196 (55.2%)	159 (44.8%)	0.102
Yes	1476 (80.6%)	885 (60.0%)	591 (40.0%)
CCP Radiotherapy
No	1225 (66.9%)	759 (62.0%)*	466 (38.0%)	< 0.001
Yes	606 (33.1%)	322 (53.1%)	284 (46.9%)*
Cetuximab cycle
Up to 4 cycles	1072 (58.5%)	618 (57.6%)	455 (42.4%)	0.125
> 4 cycles	759 (41.5%)	464 (61.1%)	295 (38.9%)
Cetuximab dose
< 400mg	996 (54.4%)	450 (45.2%)	546 (54.8%)	< 0.001
400mg	579 (31.6%)	503 (86.9%)*	76 (13.1%)
401-599mg	189 (10.3%)	114 (60.3%)*	75 (39.7%)
600-900mg	67 (3.7%)	14 (20.9%)	75 (79.1%)*
*p < 0.05, Pearson's chi-square test (n, %)

In multivariate analysis, age > 70 years presented the highest prevalence of oral mucositis, increasing 16.02 times the chances of this outcome. The female sex showed a 2.17-fold increase in the majority of oral mucositis and head and neck radiotherapy, which increased the frequency of this outcome by 1.84 times. Cetuximab treatment cycle (< 3 cycles) and dose (< 400mg) showed a 1.53- and 3.80-fold increase in the frequency of oral mucositis (Table 3).

Table 3

Multivariate analysis of risk factors for oral mucositis in patients taking cetuximab.
	p-Value	Adjusted OR	95% CI
Oral Mucositis
Sex (Female)	*0.005	2.17	1.26	3.75
Age (> 70 years old)	*<0.001	16.02	11.99	21.41
T	0.991	0.25	0.02	12.52
N	1.000	0.26	0.26	2.56
Site (CCP)	0.222	1.29	0.86	1.94
Surgery	0.245	1.32	0.83	2.09
CCP RT	*<0.001	1.84	1.41	2.40
Cetuximab Cycle (> 4 cycles)	*0.003	1.53	1.16	2.01
Cetuximabe Dose (> 600mg)	*<0.001	3.80	2.52	5.71
*p < 0.05, multinomial logistic regression; OR = adjusted odds ratio; 95% CI = 95% confidence interval of adjusted OR.

Treatment with cetuximab has been used as a line of therapy for colorectal tumors [19], refractory non-melanoma skin cancers [20], and in relapsed head and neck cancers [19], including as a second or first line of treatment [21, 2322,]. However, oral mucositis has been frankly described as a high-incidence adverse effect during the use of this monoclonal antibody [24]. In our study, the frequency of oral mucositis was 41.0%, quite similar to that described in the literature. Still, this incidence depends directly on the type of tumor treated and the antineoplastic protocol used.

A recent systematic review describes that the incidence of oral mucositis is lower when monoclonal antibodies are used compared to conventional chemotherapies [25]. Still, the incidence increases significantly when chemotherapy is used concomitantly [26]. When used as monotherapy for colorectal cancer treatment, the incidence of oral mucositis does not exceed 10% of patients [27]. During treatment for skin cancer, this adverse effect is not even mentioned as significant [28, 29]. In head and neck tumors, even when used in combination with cisplatin and/or paclitaxel, the incidence of oral mucositis related to cetuximab is 3-4.4% [30]. Still, when associated with radiotherapy, the incidence increases alarmingly to values around that observed in our study (44.7%) [31].

We also observed a low incidence of oral mucositis in non-head and neck tumors. Similar to what is described in the literature, no cases of skin cancer and only 28.3% of colorectal tumors had oral mucositis related to treatment with cetuximab. On the other hand, patients with head and neck tumors ranged from 22.9 to 89.7% incidence of oral mucositis. The factor most strongly associated with the development of oral mucositis in these tumors is the combination of cetuximab and radiation therapy. In phase I studies, > 70% of patients developed mucositis during the combination therapy [32], and these values can be as high as close to 100% [33]. In one clinical trial, the incidence of oral dermatitis and mucositis combining cetuximab and radiotherapy was more elevated than conventional treatment combining cisplatin and radiotherapy [34].

Bonner [31] state that the addition of cetuximab to radiotherapy significantly improves overall survival, progression-free survival, and loco-regional control if compared to radiotherapy alone. However, treatment with cetuximab seems to show more benefit in tumors with high EGFR expression (> 40%) [35]. Hence, although treatment with cetuximab combined with radiotherapy compared to radiotherapy alone does not significantly interfere with the quality of life of patients being treated for head and neck tumors [36], its use should be considered based on the overall health status of the patient since the addition of cetuximab to conventional treatments significantly increases the incidence of non-hematologic adverse effects, mainly cutaneous/dermal such as skin rash, hand and foot syndrome, and oral mucositis [37, 24].

Other factors that emerged as risk factors for the appearance of OM, with relevance in this study, were gender and age. The highest prevalence of mucositis was found in females and patients over 70 years of age. Although Nishii et al. (2020) evaluating patients with head and neck cancers showed a higher incidence of oral mucositis in men, several studies have shown that women have an increased risk of oral mucositis during chemotherapy [38, 39]. Female hormones show a complex and sometimes controversial association with local and systemic inflammatory processes and somehow contribute to this increase [40].

As for age, individuals over 70 years of age have a higher severity of oral mucositis, but there is no cause related to this. In general, young and elderly patients show the same clinical benefit during systemic treatment, but the fragility of health in older patients significantly increases the risk of toxicity [41]. In the present study, age was the major risk factor for oral mucositis related to treatment with cetuximab, and attention should be paid to this fact, as it may be necessary to consider the use of cetuximab in older patients given the increased adverse effects [42, 43, 44].

Severe oral mucositis leads to treatment discontinuation due to painful symptomatology of the lesions and compromises treatment prognosis [26, 25]. In the multivariate analysis of our study, we showed that sex, amount, and size of the dose but especially age are important risk factors for oral mucositis. ALONGI [ 22] and BONNER [31] describe that the increase in survival of patients with head and neck cancers treated with RT and cetuximab is only modest for patients over 70 years old, so possibly the use of cetuximab in these specific groups (women, over 70 years old and requiring high doses and a large number of cycles) should be highly considered.

Perhaps the most significant limitation of our study is its retrospective nature. It makes it impossible to track important information about prognosis and other adverse effects. However, this study shows critical risk factors to patients taking cetuximab, which may help clinical management during oncological treatment, especially head and neck tumors.

The use of cetuximab has a 41% incidence of oral mucositis. Female gender, use of radiotherapy, and especially age over 70 years old are important risk factors. Considering that the use of cetuximab in patients over 70 years presents limitations of clinical benefit, maybe this conduct should be reconsidered.

Funding:

None.

Conflicts of interest/Competing interests:

The authors have no conflicts of interest.

Availability of data and material:

Not applicable.

Code availability:

Not applicable.

Authors' contribution:

“All authors contributed to the conception and design of the study. Material preparation and data collection were carried out by Joyce Ohana de Lima Martins, Marcela Maria Fontes Borges, Cássia Emmanuela Nóbrega Malta and Lúcio Flávio Gonzaga Silva. Data analysis was performed by Paulo Goberlânio de Barros Silva. The first version of the manuscript was written by Joyce Ohana de Lima Martins, Reverton Soares Ribeiro, Janaina Motta Guerra and Bruna Carolina Coelho and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript."

Ethics approval

N/A

Consent to participate

N/A

Consent for publication

The authors declare consent for publication.

Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237–251. https://doi.org/10.1038/nrc3237
Knezevic CE, Clarke W (2020) Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring. Ther Drug Monit 42:6–19. doi:10.1097/FTD.0000000000000701
Kimiz-gebologlu I, Gulce-iz S, Biray-avci C (2018) Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep 45:2935–2940. doi:10.1007/s11033-018-4427-x
Zhang Y et al (2020) ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: a network meta-analysis of randomised clinical trials. Drugs 80: 797–811, 2020. Doi:10.1007/s40265-020-01290-3
Gillison ML, Trotti AM, Harris J (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority tria. 393:40, pg 40, 2019). Lancet 395:784–784. doi:10.1016/S0140-6736(18)32779-X
Vincenzi B et al (2010) Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10:80. doi:10.2174/156800910790980241
Mazzarella L, Guida A, Curigliano G (2018) Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther 18:483–493. doi:10.1080/14712598.2018.1452906
Moon C, Chae YK, lee J (2010) Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Experimental biology and medicine 235:907–920. doi:10.1258/ebm.2009.009181
Baldo B (2013) Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2:26333. doi:10.4161/onci.26333
Daugėlaitė G et al (2019) Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis. Medicina 55:25. doi:10.3390/medicina55020025
Lalla RV, Saunders DP, Peterson DE (2014) Chemotherapy or radiation-induced oral mucositis. Dent Clin 58:341–349. doi:10.1016/j.cden.2013.12.005
Pulito C et al (2020) Oral mucositis: the hidden side of cancer therapy. J Experimental Clin Cancer Res 39:1–15. doi:10.1186/s13046-020-01715-7
Elyasi S et al (2016) Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double-blinded, placebo‐controlled clinical trial. Phytother Res 30:1879–1885. doi:10.1002/ptr.5704
Thomas M (2005) Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs 9:332. doi:10.1188/05.cjon.332-338
Holt MH, Liu V, Fairley J (2018) Medium-vessel vasculitis presenting as multiple leg ulcers after treatment with abatacept. JAAD case reports 4:811–813. doi:10.1016/j.jdcr.2018.06.021
Malta M et al (2010) STROBE initiative: guidelines on reporting observational studies. Revista de saude publica 44:559–565. doi:10.1590/s0034-89102010000300021
Ruhl J, Adamo M, Dickie L (2016) Seer Program coding and staging manual 2016: section V. National Cancer Institute, Bethesda. 20850 – 9765, 2016. https://seer.cancer.gov/archive/manuals/2016/SPCSM_2016_maindoc.pdf
National cancer institute (2020) Common Toxicity Criteria, Version 5.0 de 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Meads C et al (2010) Cetuximab for the first-line treatment of metastatic colorectal cancer. Health Technol Assess 14:1–8. Doi:10.3310/hta14suppl1/01
Kalapurakal SJ et al (2012) Cetuximab in refractory skin cancer treatment. J Cancer 3:257doi. 10.7150/jca.3491
Mei M et al (2020) Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data. Therapeutic Adv Med Oncol 12:1–10. doi:10.1177/1758835920975355
Alongi F et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Strahlentherapie und Onkologie 188:49–55. doi:10.1007/s00066-011-0006-y
Hirasawa K et al (2017) The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients. Auris Nasus Larynx 44:724–728. Doi:10.1016/j.anl.2017.01.005
Bibault JE et al (2016) Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer. Cancer/Radiothérapie 20:357–361. doi:10.1016/j.canrad.2016.05.009
Peña-cardelles JF et al (2021) Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review. Medicina oral, patologia oral y cirugia buccal. 1:243 – 53. 10.4317/medoral.24353
Soutome S et al (2021) Risk factors for severe radiation-induced oral mucositis in patients with oral cancer. J Dent Sci 16:1241–1246. doi:10.1016/j.jds.2021.01.009
Dote S et al (2018) Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. BMC cancer 18:1–7. doi:10.1186/s12885-018-4862-z
Maubec E et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426. doi:10.1200/jco.2010.34.1735
Preneau S et al (2014) Efficacy of cetuximab in the treatment of squamous cell carcinoma. J dermatological Treat 25:424–427. doi:10.3109/09546634.2012.751481
Bossi P et al (2017) A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology 28:2820–2826. doi:10.1093/annonc/mdx439
Bonner JA et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354:567–578. doi:10.1056/nejmoa053422
Dunn LA et al (2020) A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma. Int J Radiation Oncology* Biology* Phys 106:564–570. doi:10.1016/j.ijrobp.2019.09.050
Xu T et al (2015) Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol 51:875–879. doi:10.1016/j.oraloncology.2015.06.008
Walsh L et al (2011) Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiotherapy and Oncology 98:38–41. doi:10.1016/j.radonc.2010.11.009
Vermorken JB et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359:1116–1127. doi:10.1056/nejmoa0802656
Curran D et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197. doi:10.1200/jco.2006.08.8005
Li J, YAN H (2018) Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. Cancer Chemother Pharmacol 82:571–583. doi:10.1007/s00280-018-3644-2
Gebri E et al (2020) Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation. Sci Rep 10:1–12. doi:10.1038/s41598-020-72592-5
Vokurka S et al (2006) Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer 14:974–976. Doi:10.1007/s00520-006-0031-z
Straub RH (2007) The complex role of estrogens in inflammation. Endocr Rev 28:521–574. doi:10.1210/er.2007-0001
Muss HB et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699–3704. doi:10.1200/jco.2007.10.9710
Baxi SS et al (2016) Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. Head & neck 38:E165–E171. doi:10.1002/hed.23961
Jehn CF et al (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J cancer 106:274–278. doi:10.1038/bjc.2011.554
Szturz P, Vermorken, Jan B (2016) Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol 6:2016. doi:10.3389/fonc.2016.00199

PDF

Version 1

posted 11 Apr, 2022

You are reading this latest preprint version

Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.

Status:

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

Introduction

Material And Methods

5.1. Study design and scenario

5.2. Inclusion and exclusion criteria

5.3. Socio-demographic and clinical data collection

5.4. Adverse effects analysis tool

5.5. Statistical approach

Results

Discussion

Conclusion

Declarations

References

Status:

Version 1